Drug intelligence / Profile preview

cyclophosphamide + cisplatin + tegafur

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This appears to be a theoretical combination of three chemotherapeutic agents rather than an established therapeutic regimen. **Cyclophosphamide** is an alkylating agent and nitrogen mustard that works by cross-linking DNA strands. **Cisplatin** is a platinum-based chemotherapy drug that forms DNA adducts and triggers apoptosis. **Tegafur** is a prodrug of 5-fluorouracil (5-FU) that inhibits thymidylate synthase, interfering with DNA synthesis. No clinical trials or approved indications exist for this specific three-drug combination based on available evidence.

Targets

DNATS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)

Beyond the preview

Go deeper on cyclophosphamide + cisplatin + tegafur.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + cisplatin + tegafur.

Explore the full profile